Psychiatrists play an important role in providing access to psychiatric electrical interventions (PEIs) such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). As such, their views on these procedures likely influence whether they refer or provide these types of treatments for their clinically depressed patients. Despite this, scholars have too infrequently examined psychiatrists’ views about specific PEIs and have not yet examined their views across different PEIs. To gain insight into psychiatrists’ views about PEIs, we conducted a qualitative study based on semi-structured interviews with 16 psychiatrists in Michigan. The majority of psychiatrists had a positive attitude towards PEIs in general. One-third reported cautionary attitudes towards PEIs; they did not reject the interventions but were skeptical of their effectiveness or felt they needed further development. The majority of psychiatrists consider ECT and TMS to be viable therapies that they would discuss with their patients after several failed medication trials. There was a lack of knowledge about surgical PEIs, such as deep brain stimulation. This study provides insights into how psychiatrists perceive PEIs. While broadly positive attitudes exist, this research highlights certain challenges, particularly lack of knowledge and ambiguity about the use of PEIs.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. Drug discovery: a jump-start for electroceuticals. Nature. 2013;496:159–61.
McKhann G. Stimulating the brain: electroceuticals. The Dana Foundation 1–3, 2015.Available from: http://www.dana.org/Brain_in_the_News/Stimulating_the_Brain__Electroceuticals/
Reardon S. Electroceuticals spark interest. Nature news. 2014;511:1–1.
Strickland E. Latest From SXSW: Big Pharma’s big bet on Electroceuticals. IEEE Spectr 1–3, 2016.Available from: http://spectrum.ieee.org/the-human-os/biomedical/devices/latest-from-sxsw-big-pharmas-big-bet-on-electroceuticals
Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz TL, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013;6:631–40.
Conway CR, Cristancho P, Schlaepfer TE Neurostimulation Treatments in Psychiatry: An Overview and Recent Advances Psychiatry Times 1–4, 2013.
Dell’Osso B, Oldani L, Camuri G, et al. Augmentative repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of poor responder depressed patients: a comparison study between high and low frequency stimulation. Eur Psychiatry 1–6, 2015.
Solvason HB, Husain M, Fitzgerald PB, Rosenquist P, McCall WV, Kimball J, et al. Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. Brain Stimul. 2014;7:219–25.
Weiner RD, Reti IM. Key updates in the clinical application of electroconvulsive therapy. Int Rev Psychiatry. 2017;29:54–62.
Bergfeld IO, Mantione M, Hoogendoorn MLC, Ruhé HG, Notten P, van Laarhoven J, et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression. JAMA Psychiat. 2016;73:456.
Choi KS, Riva-Posse P, Gross RE, Mayberg HS. Mapping the “depression switch” during intraoperative testing of subcallosal cingulate deep brain stimulation. JAMA Neurol. 2015;72:1252–60.
Ilse G, Martijn F, Damiaan D. The application of deep brain stimulation in the treatment of psychiatric disorders. International Review of Psychiatry 0: −000, 2017.
Lipsman N, Sankar T, Downar J, Kennedy SH, Lozano AM, Giacobbe P. Neuromodulation for treatment-refractory major depressive disorder. Can Med Assoc J. 2014;186:33–9.
Pierce RC, Vassoler FM. Deep brain stimulation for the treatment of addiction: basic and clinical studies and potential mechanisms of action. Psychopharmacology. 2013;229:487–91.
Fins JJ, Mayberg HS, Nuttin BJ, Kubu CS, Galert T, Sturm V, et al. Misuse of the FDA's humanitarian device exemption in deep brain stimulation for obsessive-compulsive disorder. Health Aff. 2011;30:302–11.
Shen H. Tuning the brain. Nature. 2014;507:290–2.
Yue Z, Moulton SE, Cook M, O'Leary S, Wallace GG. Controlled delivery for neuro-bionic devices. Adv Drug Deliv Rev. 2013;65:559–69.
Dauenhauer LE, Chauhan P, Cohen BJ. Factors that influence electroconvulsive therapy referrals. J ECT. 2011;27:232–5.
Finch JM, Sobin PB, Carmody TJ, et al. A survey of psychiatrists’ attitudes toward electroconvulsive therapy. Psychiatr Serv. 1999;1–2.
Lutchman RD, Stevens T, Bashir A, et al. Mental health professionals' attitudes towards and knowledge of electroconvulsive therapy. J Ment Health. 2009;10:141–50.
Schweder LJ-V, Lydersen S, Wahlund B, Bergsholm P, Linaker OM. Electroconvulsive therapy in Norway. J ECT. 2011;27:292–5.
Stern AP, Boes AD, Haller CS, Bloomingdale K, Pascual-Leone A, Press DZ. Psychiatrists' attitudes toward transcranial magnetic stimulation. Biol Psychiatry. 2016;80:e55–6.
Ali R, DiFrancesco MF, Ho AL, et al. Attitudes toward treating addiction with deep brain stimulation. Brain Stimulation. 2016;9:1–3.
Cormier J, Iorio-Morin C, Mathieu D, Ducharme S. Psychiatric neurosurgery: a survey on the perceptions of psychiatrists and residents. Can J Neurol Sci. 2019;46:303–10.
Naesstr M, Blomstedt P, Hariz M, Bodlund O. Deep brain stimulation for obsessive-compulsive disorder: knowledge and concerns among psychiatrists, psychotherapists and patients. Surg Neurol Int. 2017;8:298–6.
Cabrera LY, Courchesne C, Kiss ZHT, et al. Clinical perspectives on psychiatric neurosurgery. Stereotact Funct Neurosurg. 2020;97:391–8.
Sadowsky J. Electroconvulsive therapy in America. Routledge, 2017.
Frank L. The pleasure shock. Penguin, 2018.
Marshall C, Rossman GB. Designing Qualitative Research, 6th ed. SAGE, 2016.
Miles MB, Huberman AM, Saldaña J. Qualitative Data Analysis. SAGE, 2013.
Hsieh HF. Three approaches to qualitative content analysis. Qual Health Res. 2005;15:1277–88.
Sandelowski M. Focus on research methods whatever happened to qualitative description? Res Nursing Health. 2000;23:334–40.
Bhriain SN, Malone K. ECT: a controversial but effective treatment. Ir J Psychol Med. 2003;20:74–6.
Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. JAMA Psychiat. 2018;75:713–0.
Donahue AB. Electroconvulsive therapy and memory loss. J ECT. 2000;16:133–43.
Beale MD, Kellner CH. ECT in treatment algorithms: no need to save the best for last. J ECT. 2000;16:1–2.
Hariz M, Blomstedt P, Zrinzo L. Future of brain stimulation: new targets, new indications, new technology. Mov Disord. 2013;28:1784–92.
Klein E, Goering S, Gagne J, et al. Brain-computer interface-based control of closed- loop brain stimulation: attitudes and ethical considerations. Brain-Computer Interfaces 1–9, 2016.
Kalayam B, Steinhart MJ. A survey on the use of electroconvulsive. Hosp Community Psychiatry. 1981;32:1–4.
Kerr RA, McGrath JJ, O'kearney RT, et al. ECT: misconceptions and attitudes. Australian & New Zealand J Psychiat. 2009;16:43–9.
McDonald A, Walter G. The portrayal of ECT in American movies. J ECT. 2001;17:264–74.
Walter G. About to have ECT? Fine, but don't watch it in the movies: the sorry portrayal of ECT in film. Psychiatr Times. 2004;21:65–5.
We further thank our participants for their time and insightful responses. We also thank Marissa Cortright and Emily Castillo for their support in coding the interviews.
Availability of Data and Material
Access to interview data is available upon request.
This work was supported by the NIH BRAIN-NIMH under Grant number: 1RF1MH117802–01, PI: LC.
Conflict of Interest
LC, RB, and AM have no conflicts of interest to declare. EA has received research support from the following entities in the preceding 12 months: Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR, Janssen, National Network of Depression Centers, Neurocrine Biosciences, Novartis, Otsuka, Pear Therapeutics, Takeda, and the Vanguard Research Group. He has also served on advisory boards or consulted with: Alkermes, F. Hoffman-La Roche, Janssen, Otsuka/Lundbeck, and Sunovion.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Cabrera, L.Y., Nowak, G.R., McCright, A.M. et al. Last Resort Interventions?: A Qualitative Study of Psychiatrists’ Experience with and Views on Psychiatric Electroceutical Interventions. Psychiatr Q 92, 419–430 (2021). https://doi.org/10.1007/s11126-020-09819-1
- Electroconvulsive therapy
- Deep brain stimulation
- Transcranial magnetic stimulation